Cibc World Markets Corp Buys Shares of 4,579 Glaukos Co. (NYSE:GKOS)

Cibc World Markets Corp purchased a new stake in shares of Glaukos Co. (NYSE:GKOS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,579 shares of the medical instruments supplier’s stock, valued at approximately $687,000.

Several other institutional investors have also made changes to their positions in GKOS. Natixis Advisors LLC lifted its holdings in shares of Glaukos by 1.2% during the 3rd quarter. Natixis Advisors LLC now owns 37,738 shares of the medical instruments supplier’s stock valued at $4,917,000 after buying an additional 441 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Glaukos by 3.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 43,152 shares of the medical instruments supplier’s stock valued at $5,622,000 after buying an additional 1,339 shares during the last quarter. Pathstone Holdings LLC lifted its holdings in shares of Glaukos by 6.3% during the 3rd quarter. Pathstone Holdings LLC now owns 22,449 shares of the medical instruments supplier’s stock valued at $2,925,000 after buying an additional 1,326 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Glaukos in the 3rd quarter worth approximately $1,347,000. Finally, Jennison Associates LLC acquired a new stake in Glaukos in the 3rd quarter worth approximately $792,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Stephens upgraded Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th. BTIG Research boosted their target price on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Truist Financial boosted their target price on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Finally, Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and an average target price of $163.25.

Glaukos Stock Performance

GKOS opened at $102.02 on Friday. The stock has a market cap of $5.77 billion, a PE ratio of -35.55 and a beta of 0.99. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 1 year low of $87.59 and a 1 year high of $163.71. The stock’s 50 day simple moving average is $135.32 and its 200-day simple moving average is $136.55.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Sell-side analysts forecast that Glaukos Co. will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.